Open AccessEfficacy of BRAF‐Inhibitor Therapy in BRAF V600E ‐Mutated Adult Langerhans Cell Histiocytosis
Author(s) -
Hazim Antonious Z.,
Ruan Gordon J.,
Ravindran Aishwarya,
Abeykoon Jithma P.,
Scheckel Caleb,
Vassallo Robert,
Ryu Jay H.,
Tobin W. Oliver,
Koster Matthew J.,
Bennani N. Nora,
Rech Karen L.,
Young Jason R.,
Shah Mithun V.,
Goyal Gaurav,
Go Ronald S.
Publication year - 2020
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13541
Subject(s) - langerhans cell histiocytosis , medicine , dabrafenib , trametinib , histiocytosis , vemurafenib , targeted therapy , histiocyte , oncology , pathology , cancer , disease , metastatic melanoma , mapk/erk pathway , kinase , biology , microbiology and biotechnology
Langerhans cell histiocytosis (LCH) is a rare histiocytic neoplasm. To date, there is a lack of U.S. Food and Drug Administration–approved treatments in adult LCH to establish optimal first‐line therapy. We conducted a retrospective, single‐center case series evaluating the use of BRAF inhibitors in adult patients with BRAF V600E ‐ LCH proven by biopsy. Our case series is the first to report the use of BRAF inhibitors as first‐line therapy in adults with LCH. We also report the efficacy with single‐agent dabrafenib in adult LCH. All but one of our patients had favorable response to targeted therapy.